Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer

Antonio Passaro, Daniele Alesini, Alessia Pochesci, Enrico Cortesi

Research output: Contribution to journalArticle

Abstract

Erlotinib and gefitinib are tyrosine kinase inhibitors (TKI) associated with the EGFR, which is involved in cell proliferation, growth, migration, invasion and survival, and has been found to be overexpressed in non-small-cell lung cancer. Erlotinib was the first target agent approved for the treatment of NSCLC in second-and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. In elderly patients, with a poor prognosis, and different co-morbidities, erlotinib and gefitinib could be considered as valid therapeutic options. This paper reviews the role of both drugs, in the management of elderly patients affected by advanced NSCLC based on an update analysis of randomised and non-randomised clinical trials.

Original languageEnglish
Pages (from-to)646-650
Number of pages5
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume14
Issue number5
DOIs
Publication statusPublished - 2014

Keywords

  • Egfr
  • Elderly
  • Erlotinib
  • Gefitinib
  • Non-small-cell lung cancer
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this